Abstract
Allergic rhinitis has increased in the last fifty years from affecting less than a percent to more than twenty-six percent of the population. Today, more than one hundred million people in the US suffer from these seasonal or yearlong allergies. The hygiene hypothesis was proposed 30 years ago as a potential explanation for this phenomenon, and we built on that with the specific oral hygiene hypothesis. Our longitudinal pilot study suggested that oral probiotic deficiency is the cause of allergic rhinitis. This clinical trial served to verify our theory and evaluate the effectiveness of AllerPops for allergy relief. Through it, we show that AllerPops prebiotic supplements are effective in providing sustained allergy relief (p = 0.002) and can modulate oral beneficial bacteria that produce short-chain fatty acids (SCFA), such as Fusobacteria, Butyrivibrio, and Peptostreptococcus. The clinical improvements correlated with changes in the relative abundance of probiotics significantly: Fusobacteria (R = 0.32, p = 0.009), Butyrivibrio (R = 0.25, p = 0.044), and Peptostreptococcus (R = 0.34, p = 0.005). These results point to the root cause of allergic rhinitis: the lack of oral probiotics that produce SCFA to pacify the immune systems. Future study of AllerPops’ theory will help society redefine the best oral hygiene practice to protect oral probiotics so that we may prevent allergic and autoimmune diseases and dental/gum infections. The trial was retrospectively registered at clinicaltrials.com, with registration number NCT05956691, on 21/07/2023.
Competing Interest Statement
Cliff Shunsheng Han is the founder and Owner of AllerPops Corp.
Clinical Trial
NCT05956691
Funding Statement
Private fund
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Canada approved the study design with protocol number 21-SAHSE-01, and Advarra Institutional Review Board (Aurora, ON, Canada) give ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The discussion has been updated with recent research about food allergies and emphasizes the three SCFA producers associated with allergic rhinitis.
DATA AVAILABILITY
Sequence data related to this clinical trial is available at Sequence Read Archive, https://www.ncbi.nlm.nih.gov/bioproject/978635, with BioProject ID PRJNA978635.
